Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes: A survey of 1075 cases from EUROAPS registry∗

Sara De Carolis, Jaume Alijotas-Reig, Enrique Esteve-Valverde, Raquel Ferrer-Oliveras, Luis Sáez-Comet, Elmina Lefkou, Arsène Mekinian, Cristina Belizna, Amelia Ruffatti, Angela Tincani, Josep Pardos-Gea, Cecilia Nalli, Luca Marozio, Gerard Espinosa, Omar Latino, Udry Sebastian, Elisa Llurba, Laura Trespidi, Cecilia Chighizola, Vittorio PengoPatrizia Rovere-Querini, Valentina Canti, Karoline Mayer-Pickel, Tatiana Reshetnyak, Sara Tabacco, Anna Arnau

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

BACKGROUND: The combination of low-dose aspirin (LDA) and low-molecular-weight heparin (LMWH) until the end of gestation are the currently the accepted standard of care for the treatment of antiphospholipid-related obstetric disorders. In refractory cases, hydroxychloroquine (HCQ) can be added to this standard of care. OBJECTIVE: To evaluate the haemostatic safety of LDA and LMWH (medium to high prophylactic doses) during pregnancy and the puerperium in women with both full-blown obstetric antiphospholipid syndrome (OAPS) (Sydney criteria) and noncriteria - incomplete - OAPS. STUDY DESIGN: Retrospective/prospective multicentre observational study. Obstetric background, laboratory categories, delivery mode, antithrombotic regimens and bleeding complications were compared. SETTING: A total of 30 tertiary European hospitals. PATIENTS: Mainly, Caucasian/Arian pregnant women were included. Other ethnicities were minimally present. Women were controlled throughout pregnancy and puerperium. MAIN OUTCOME MEASURES: The primary end-point was to evaluate the number of major and minor haemorrhagic complications in this cohort of women. Neuraxial anaesthetic bleeding complications were particularly assessed. Secondly, we aimed to compare local/general bleeding events between groups. RESULTS: We studied 1650 women, of whom 1000 fulfilled the Sydney criteria of the OAPS and 650 did not (noncriteria OAPS). Data on antithrombotic-related complications were available in 1075 cases (65.15%). Overall, 53 (4.93%) women had bleeding complications, with 34 being considered minor (3.16%) and 19 major (1.76%). Neither obstetric complications nor laboratory categories were bleeding-related. Assisted vaginal delivery and caesarean section were related to local haemorrhage. Heparin doses and platelet count were not associated with major bleeding. CONCLUSIONS: LDA and medium to high prophylactic LMWH during pregnancy in women with full-blown OAPS/noncriteria OAPS are safe. A slight increase in bleeding risk was noted in instrumental deliveries. No women who underwent spinal or epidural anaesthesia suffered bleeding complications. No haemorrhage was observed in cases where HCQ was added to standard therapy.
Lingua originaleEnglish
pagine (da-a)916-922
Numero di pagine7
RivistaEuropean Journal of Anaesthesiology
Volume38
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Cesarean Section
  • Female
  • Hemorrhage
  • Heparin, Low-Molecular-Weight
  • Humans
  • Pregnancy Complications
  • Prospective Studies
  • Registries
  • Retrospective Studies
  • Fibrinolytic Agents
  • Pregnancy

Fingerprint

Entra nei temi di ricerca di 'Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes: A survey of 1075 cases from EUROAPS registry∗'. Insieme formano una fingerprint unica.

Cita questo